Tarloxotinib

Drug Profile

Tarloxotinib

Alternative Names: Hypoxin™; PR 610; Tarloxotinib bromide; TH-4000

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator University of Auckland
  • Developer Proacta; Threshold Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 29 Sep 2016 Discontinued - Phase-II for Non-small cell lung cancer (Second-line therapy or greater) in Australia, USA (IV) due to insignificant data
  • 29 Sep 2016 Discontinued - Phase-II for Squamous cell cancer (Metastatic disease, Recurrent) in USA, Australia (IV) due to insignificant data
  • 29 Sep 2016 Interim efficacy data from two phase II trials (TH-CR-601 and TH-CR-602 in Non-small cell lung cancer and squamous cell cancer released by Threshold Pharmaceuticals (9204317)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top